Patents Examined by Ebenezer O. Sackey
  • Patent number: 10975352
    Abstract: The present invention relates compounds for stabilizing cells and methods of their use.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: April 13, 2021
    Assignee: The Scripps Research Institute
    Inventors: Yue Xu, Sheng Ding
  • Patent number: 10975034
    Abstract: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: April 13, 2021
    Assignee: CYTOKINETICS, INC.
    Inventors: Bradley Paul Morgan, Alex Muci, Pu-Ping Lu, Erica Anne Kraynack, Todd Tochimoto, David J. Morgans, Jr.
  • Patent number: 10973816
    Abstract: Processes for providing depot injections of recrystallized aripiprazole lauroxil in which particles of the aripiprazole lauroxil have a surface area of about 0.50 to about 3.3 m2/g; and crystals of aripiprazole lauroxil produced by such processes.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: April 13, 2021
    Inventors: Wilfredo Morales, Tarek A. Zeidan, Renato A. Chiarella, Steven G. Wright, Jason M. Perry
  • Patent number: 10975094
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: April 13, 2021
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Jianming Yu, Solymar Negretti-Emmanuelli, In Jong Kim, Yat Sun Or
  • Patent number: 10975058
    Abstract: The present disclosure provides imidazolyl compounds of Formula (I) and methods of preparing the compounds. The provided compounds are able to bind protein kinases and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase in a subject or cell and/or in treating or preventing a disease (e.g., proliferative disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: April 13, 2021
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, Hwan Geun Choi, Yanke Liang
  • Patent number: 10968184
    Abstract: This invention relates to pyrimidine prodrug derivatives, processes for their preparation, pharmaceutical compositions, and their use in therapy.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: April 6, 2021
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Jérôme Émile Georges Guillemont, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, David Craig McGowan, Werner Constant Johan Embrechts, Bart Henri Theresia Stoops, Florence Marie Herschke, Jacques Armand Henri Bollekens, Laurent Jacques Emile Calmus
  • Patent number: 10961242
    Abstract: The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same. The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: March 30, 2021
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Dae Yon Lee, Sang Eun Chae, Eun Mi Jung, Eun Hye Yang, Yoon Jeong Choi, Chul-Woong Chung, Ju Hyun Shin, Yun Ki Kim, Hyun Jin Kwon, Jeong Hee Ryu, Eun Hye Ban, Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae
  • Patent number: 10961187
    Abstract: Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: March 30, 2021
    Assignee: Promentis Pharmaceuticals, Inc.
    Inventors: Michael Neary, James Nieman, Steven Tanis, Daniel Lawton, Garry Smith
  • Patent number: 10961254
    Abstract: The present invention relates to 2-amino-4-arylpyrimidine and 2-amino-4-aryltriazine compounds as inhibitors of heat shock protein 90 family of chaperone proteins. The invention also features pharmaceutical compositions and kits that include the compounds and compositions of the invention. The invention further relates to the medical use of these compounds and compositions for the treatment of a disorder in a subject. For example, the disorder is a neurodegenerative disease.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: March 30, 2021
    Assignees: Yuma Therapeutics, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Gregory D. Cuny, Marcie A. Glicksman, Kevin J. Hodgetts, Steven L. Mathieu, Yukari Y. Perrella, Vincent Darmency, Hrvoje Lusic
  • Patent number: 10960003
    Abstract: The present invention provides pyrazole pyrimidine derivatives which inhibit Casein kinase I (CKI) and/or Interleukin-1 receptor-associated kinase 1 (IRAKI) and methods of their manufacture, compositions comprising them and uses thereof in methods of treating malignant disease and disorders and methods for treating inflammatory diseases and disorders.
    Type: Grant
    Filed: August 12, 2019
    Date of Patent: March 30, 2021
    Assignee: BioTheryX, Inc.
    Inventors: Yinon Ben Neriah, Guy Brachya, Ido Burstain, Waleed Minzel, Irit Snir-Alkalay, Joseph Vacca, Dansu Li
  • Patent number: 10954232
    Abstract: The present disclosure relates to a novel substituted pyrazole derivative having an effect of inhibiting serine/threonine kinase activity targeting receptor ALK5 of TGF-?, and a pharmaceutical composition including the compound of the present disclosure as an active ingredient may be useful in preventing and/or treating cancers, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, pulmonary diseases, cardiovascular diseases or metabolic diseases, or other diseases associated with a decrease in TGF family signaling activity.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: March 23, 2021
    Inventors: Kyung Ik Lee, Young Hee Jung, Ji Young Song, Seung Ah Jun
  • Patent number: 10954217
    Abstract: Provided herein, inter alia, are compounds and methods of treating diseases including cancer, neurological disease, alcohol withdrawal, depression and anxiety, and neuropathic pain.
    Type: Grant
    Filed: April 29, 2017
    Date of Patent: March 23, 2021
    Inventors: Stephen F. Martin, James J. Sahn, Kathryn Taylor Linkens
  • Patent number: 10946016
    Abstract: The present invention provides a solid form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: March 16, 2021
    Assignee: Celgene CAR LLC
    Inventor: Mei Lai
  • Patent number: 10941115
    Abstract: There are provided compounds of formula I, wherein R1A to R1E, R2 to R4, R5a, L and X1 to X3 have meanings given in the description, which compounds have anti-inflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: March 9, 2021
    Assignee: Oxular Acquisitions Limited
    Inventors: Thomas Matthew Baker, Matthew Colin Thor Fyfe, Geraint Jones, Stephen Malcolm Thom
  • Patent number: 10934315
    Abstract: The present disclosure provides a process for preparing Bortezomib, intermediates, and crystalline forms thereof.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: March 2, 2021
    Inventors: Wei-Hong Tseng, Vallapa Soong, Hsing Yu Chang, Shen Han Yang
  • Patent number: 10937970
    Abstract: A compound of Chemical Formula 1, and a photoelectric device, an image sensor, and an electronic device including the same are disclosed: In Chemical Formula 1, each substituent is the same as defined in the detailed description.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: March 2, 2021
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Taejin Choi, Sang Mo Kim, Sung Young Yun, Youn Hee Lim, Katsunori Shibata, Hiromasa Shibuya, Gae Hwang Lee, Norihito Ishii, Dong-Seok Leem, Yong Wan Jin, Yeong Suk Choi, Jong Won Choi, Hyesung Choi
  • Patent number: 10927070
    Abstract: Provided herein are compositions and methods for treating, inhibiting and/or reducing the severity of cancer in subjects in need thereof. The methods include providing an agent that inhibits expression or activity of ONECUT2 and administering a therapeutically effective amount of the agent so as to treat, inhibit and/or reduce the severity of cancer in the subject.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: February 23, 2021
    Assignee: Cedars-Sinai Medical Center
    Inventors: Michael Freeman, Mirja Rotinen, Ramachandran Murali, Sungyong You
  • Patent number: 10913747
    Abstract: Object of the present invention is an efficient process for the preparation of the active pharmaceutical ingredient Sitagliptine and the 2,4,5-trifluorophenylacetic acid (TFAA) and salt thereof, which is a key intermediate for the synthesis of Sitagliptine.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: February 9, 2021
    Inventors: Ottorino De Lucchi, Pierluigi Padovan, Elena Brasola
  • Patent number: 10906878
    Abstract: The invention relates to compounds and their use in the treatment of disease. Novel irreversible inhibitors of wild-type and mutant forms of EGFR, FGFR, ALK, ROS, JAK, BTK, BLK, ITK, TEC, and/or TXK and their use for the treatment of cell proliferation disorders are described.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: February 2, 2021
    Inventors: Nathanael S. Gray, Hwan G. Choi, Li Tan
  • Patent number: 10905768
    Abstract: This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) (“Degrons”), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: February 2, 2021
    Assignee: C4 Therapeutics, Inc.
    Inventors: Andrew J. Phillips, Chris G. Nasveschuk, James A. Henderson, Yanke Liang, Mark E. Fitzgerald, Minsheng He, Ryan E. Michael